new_banner

news

N-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl) thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide

Darafenib intermediate 5(CAS 1195768-23-0), is the key thiazole-pyrimidine building block of the BRAF inhibitor darafenib (Dabrafenib). The product is a light yellow to yellow solid with clear requirements for inert atmosphere and low temperature storage, and is mainly used for the construction and commercial supply of targeted anti-tumor APIs.

List of product parameters

Name darafenib intermediate 5;N-(3-(2-(tert-butyl)-5-(2-chloropyrimidin-4-yl) thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
Alias N-(3-(2-(tert-Butyl)-5-(2-chloropyrimidin-4-yl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide
CAS No. 1195768-23-0
chemical formula C₂ H₂ Cl2 ClF₂ N₂ O₂ (most authoritative sources)
molecular weight 538.99
InChI InChI=1S/C23H18ClF3N4O2S2/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(24)29-16)12-6-4-9-15(17(12)27)31-35(32,33)20-13(25)7-5-8-14(20)26/h4-11,31H,1-3H3
density 1.5±0.1g/cm³ (predicted)
boiling Point 635.5±65.0°C at 760 mmHg (predicted)
flash Point 338.1±34.3°C (predicted)
water soluble insoluble in water (presumed based on high LogP hydrophobicity characteristics)
vapor pressure 0.0±1.9 mmHg at 25°C (Predicted)
refractive index 1.613 (predicted)
storage conditions 2-8°C, inert atmosphere protection
sensitivity air/moisture sensitive, inert atmosphere operation recommended
appearance light yellow to yellow solid
specific Gravity approximately 1.5 (consistent with density values)
color pale yellow to yellow
dangerous Goods Signs reference similar sulfonamide/pyrimidine intermediate: GHS07 (exclamation mark), warning word Warning
risk Terms reference values: H315 (skin irritation), H319 (severe eye irritation), H335 (respiratory irritation)
safety terminology reference value: P261, P305 + P351 + P338 (avoid inhalation; rinse thoroughly after entering eyes)
customs Number 2935900090 / 38229010 (different source calibre, actual according to the latest tax rules and reporting purposes)

nature

this product is a fluorine-containing, chlorine-containing polyheterocyclic sulfonamide solid. There are pyrimidine ring, thiazole ring, 2-fluorophenyl and 2,6-difluorobenzenesulfonamide fragments in the molecule at the same time. The conjugated system and multiple electron withdrawing groups make it have high thermal stability prediction value (boiling point 635.5°C, flash point 338.1°C), but the 2-chloropyrimidine end has substitution sensitivity under strong nucleophilic/strong alkaline conditions. The compounds have strong hydrophobicity (LogP about 4.12) and low water solubility, and are suitable for subsequent coupling or amination reactions in polar aprotic solvent systems.

Use

this product is the key upstream intermediate of Dalafeni (Dabrafenib, GSK2118436). Darafenib is a second-generation BRAF inhibitor, which is used for targeted therapy of BRAF V600 mutation-positive melanoma and non-small cell lung cancer by competitively binding to the ATP-binding domain of BRAF V600 mutant and blocking the MEK-ERK signaling pathway. The intermediate assumes the assembly function of the “thiazole-pyrimidine-fluorobenzene sulfonamide” skeleton in the process route, and its 2-chloropyrimidine site is the key reaction site for introducing amino groups and completing the structural modification of the end of darafenib.

Safety Information

according to the general hazard classification of structural analogs and sulfonamide/halogenated heterocyclic intermediates, the operation should be regarded as having skin/eye irritation and respiratory tract irritation (H315/H319/H335). It is recommended to handle in a fume hood, wear protective gloves, goggles and experimental clothes to avoid direct contact with skin by dust inhalation. Storage must be sealed in an inert atmosphere at 2-8°C, away from strong oxidants, strong acids and strong bases. This product is limited to research and development and industrial production use, not for human or clinical diagnosis.

Our production advantages and capacity

Shanghai Lizhuo Pharmaceutical Technology Co., Ltd. (Shanghai Lizhuo Pharmaceutical Technology Co., Ltd.) focuses on the research and development and production of pharmaceutical intermediates. It has realized the industrial large-scale production of many difficult intermediates. Its products have won continuous trust in domestic and foreign markets with high purity and reliable supply capacity. For Darafenib intermediate 5 and similar targeted anti-tumor building blocks, our core competitiveness is reflected in the following aspects:

flexible supply capacity: covering continuous demand from kilogram-level research and development screening to ton-level commercial production, taking into account the small-volume flexibility of early projects and the supply stability of later scale-up.

Process and quality barriers: process development and optimization capabilities from starting materials to intermediates, mature engineering control experience in sensitive steps such as fluorine-containing heterocycles and sulfonamide fragments, and high quality consistency between batches.

Industrialization platform support: relying on its own production base and continuous upgrading of the production capacity layout, key intermediates can achieve large-scale release, reduce the risk of customer supply chain interruption.

Market verification: The company participated in CPHI China and other international platforms, high-purity intermediate products have been formed in domestic and foreign customers to form a stable re-purchase, quality and delivery records can be traced back.

If you need to obtain the current batch COA, SDS, inventory status and ton-level supply schedule of this product, please contact the technical and business team directly through official website.

FAQ: The 5 Most Concerned Buyers

q1: What is the conventional purity of this intermediate? Does it support custom specifications? A: Our company can provide conventional purity grades of ≥ 97% to ≥ 99% for darafenib intermediate 5, and can carry out specific impurity profile control and packaging specification customization according to customer’s downstream process requirements. COA is provided with each batch, and limits can be negotiated for key impurities.

Q2: From kg to ton, what is the supply cycle and capacity elasticity? A: Our company adopts flexible production line, and kilogram samples can be delivered in a short period of time. Ton orders are supplied on a rolling basis according to the scheduling plan. The company has a continuous supply capacity from kg to ton, which is suitable for different rhythms of pre-clinical research, clinical stage and commercial production.

Q3: Why do storage conditions require 2-8°C inert atmosphere? How to guarantee during transportation? A: This intermediate is air/moisture sensitive, and high temperatures or exposure to moisture may cause degradation or growth of impurities. Sealed, light-proof and low-temperature packaging scheme is adopted for transportation. Cold chain or heat insulation packaging can be selected according to the destination and transportation time limit to ensure the delivery quality is consistent with COA.

Q4: Does your company have regulatory support documents (SDS, regulatory statement) for this product? A: Our company can provide SDS, COA and regulatory support documents that meet the requirements when necessary. Due to the limited public SDS data of the CAS, our company has established safe operation and storage specifications based on the actual process and structural characteristics. The specific document requirements can be connected by the technical team when inquiring.

Q5: What is the core reason for choosing Shanghai Lizhuo compared to other suppliers? A: Three points: supply certainty (flexible production capacity from kg to ton, reducing the risk of supply interruption), quality consistency (process controlled, batch traceability, high-purity products have been verified by the market), response efficiency (direct docking of technology and commerce, short link from specification confirmation to production scheduling and delivery). We not only sell an intermediate, but also provide sustainable cooperation solutions from the process end to the supply end.

Welcome to visit our official website to obtain the product page, contact information and the latest capacity trends: https://www.shlzpharma.com/

 


Post time: Nov-18-2026